Conditions Treated

Dr. Katherine Unverferth is a board-certified psychiatrist specializing in reproductive psychiatry and women's mental health. She provides individualized psychiatric care for adults experiencing depression, anxiety, and other mental health concerns, with particular expertise in conditions influenced by reproductive hormonal changes.

Her Santa Monica private practice offers comprehensive psychiatric evaluations and medication management, with a particular focus on conditions influenced by hormones, including perinatal depression, postpartum obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), and perimenopausal depression and anxiety. Dr. Unverferth collaborates closely with OB/GYNs, hormone specialists, primary care physicians, and therapists to provide comprehensive, coordinated care.

In addition to her private practice, Dr. Unverferth serves as Director of the UCLA Women's Life Center, Medical Director of the UCLA Maternal Mental Health Program, and Assistant Clinical Professor at the David Geffen School of Medicine at UCLA. She lectures nationally on reproductive psychiatry and was the recipient of the 2026 UCLA Department of Psychiatry Teaching Award.

Premenstrual Dysphoric Disorder (PMDD)

Premenstrual dysphoric disorder (PMDD) is a hormonally sensitive mood disorder characterized by symptoms that emerge during the luteal phase of the menstrual cycle. Symptoms may include depression, irritability, anxiety, mood swings, and difficulty functioning in relationships, at work, or in daily life. Symptoms typically resolve shortly after menstruation begins, with a period of minimal or absent symptoms during the follicular phase. PMDD can occur from adolescence through the menopausal transition, and Dr. Unverferth treats women with this condition across the reproductive lifespan.

Dr. Unverferth has extensive clinical and academic expertise in PMDD. She lectures nationally on its diagnosis and treatment, co-authored the chapter "Premenstrual Mood Syndromes" in the APA Textbook of Women's Reproductive Mental Health, and co-developed PMDD educational materials for the National Curriculum in Reproductive Psychiatry (NCRP). She also serves as NCRP faculty and is recognized by the International Association for Premenstrual Disorders (IAPMD) as a PMDD-specific provider.

In 2026, she presented on PMDD at the American Psychiatric Association Annual Meeting, Santa Clara Valley Medical Center Psychiatry Grand Rounds, and the National Reproductive Psychiatry Interest Group. She has also provided expert commentary on PMDD for National Geographic and NPR/LAist's AirTalk.

Her approach emphasizes careful diagnostic evaluation, including prospective symptom tracking when appropriate, and evidence-based treatment that may include selective serotonin reuptake inhibitors (SSRIs), hormonal interventions, and psychotherapy.

She also evaluates and treats premenstrual exacerbation (PME), in which symptoms of an underlying psychiatric condition worsen during the premenstrual phase.

Depression and Anxiety During Pregnancy

Pregnancy involves dramatic hormonal and physiological changes that can impact a woman's mental health. Estrogen and progesterone levels increase substantially throughout pregnancy, and women who are sensitive to hormonal changes may experience new or worsening symptoms of depression or anxiety.

Dr. Unverferth provides specialized psychiatric care for women experiencing depression and anxiety during pregnancy, including individualized assessment, treatment planning, and medication management. She serves as Director of the UCLA Women's Life Center and Medical Director of the UCLA Maternal Mental Health Program, where she oversees specialized psychiatric care for pregnant and postpartum women.

Dr. Unverferth has extensive experience teaching evidence-based psychiatric treatment during pregnancy. She has lectured on depression in pregnancy at UCLA Psychiatry Grand Rounds and the National Psychopharmacology Update, and regularly teaches UCLA psychiatry residents and fellows about medication safety, pregnancy outcomes, and individualized risk-benefit assessment. She has also provided expert commentary on antidepressant safety during pregnancy for the Los Angeles Times and other media outlets.

A central component of her approach is carefully weighing the risks of untreated depression and anxiety against the potential risks of psychiatric medication use during pregnancy. Treatment is individualized and may include antidepressants and other psychiatric medications, psychotherapy recommendations, and coordination with OB/GYNs and other healthcare providers. Dr. Unverferth also provides preconception consultations for women planning pregnancy who have questions about continuing or adjusting their psychiatric medications.

Postpartum Depression and Anxiety

The postpartum period is associated with some of the most dramatic hormonal changes in a woman's life. During pregnancy, estrogen and progesterone levels increase substantially, reaching levels many times higher than their typical menstrual cycle levels before declining rapidly after delivery. While these hormonal changes are expected, some women are particularly sensitive to the rapid decline in reproductive hormones and may develop postpartum depression or anxiety.

Postpartum depression and anxiety may involve persistent sadness, difficulty bonding with the infant, intense worry, feelings of guilt, difficulty sleeping even when the infant is sleeping, and intrusive thoughts. Symptoms can range in severity and may significantly affect a woman's functioning and quality of life.

Dr. Unverferth has extensive experience evaluating and treating postpartum depression and anxiety, including complex presentations requiring a higher level of psychiatric care. As Medical Director of UCLA's Maternal Mental Health Program, she oversees a specialized Perinatal Intensive Outpatient Program for women experiencing significant psychiatric symptoms during pregnancy and postpartum.

Dr. Unverferth lectures nationally on postpartum depression, including its hormonal underpinnings, diagnosis, and emerging treatment options. She has presented at UCLA Psychiatry Grand Rounds and Postpartum Support International, and was selected as an invited faculty group leader for the 2026 Postpartum Depression in Practice educational program through Albert Einstein College of Medicine and Postpartum Support International. She recently led the revision of the Perinatal Depression module for the National Curriculum in Reproductive Psychiatry (NCRP).

Dr. Unverferth has particular expertise in emerging treatments for postpartum depression, including the neuroactive steroid zuranolone, transcranial magnetic stimulation (TMS), and ketamine-based treatments. She has lectured extensively on these treatments and served on national and international advisory boards focused on postpartum depression treatment and research. Her expertise has been featured on CNN and in the Los Angeles Times, The Times (UK), Women's Health, Parade, and NPR/LAist, among other publications and media outlets.

Treatment is individualized and may include antidepressants, newer treatments for postpartum depression such as zuranolone, psychotherapy recommendations, and coordination with other members of a patient's care team. When appropriate, Dr. Unverferth also considers referrals for TMS and ketamine-based treatment.

Postpartum Obsessive-Compulsive Disorder (OCD)

Perinatal obsessive-compulsive disorder (OCD) is characterized by unwanted, intrusive thoughts, images, or urges that cause significant distress and may be accompanied by reassurance seeking, avoidance, or other compulsive behaviors. Intrusive thoughts in the postpartum period often revolve around an infant's safety or health, but can also relate to contamination, symmetry, personal health concerns, and other themes.

These intrusive thoughts are typically experienced as unwanted and inconsistent with the individual's values and intentions. Distinguishing postpartum OCD from other psychiatric conditions, including postpartum psychosis, is an important part of clinical assessment.

As Medical Director of UCLA's Maternal Mental Health Program, Dr. Unverferth has extensive experience treating complex presentations of perinatal OCD. She has training in cognitive behavioral therapy (CBT) and exposure and response prevention (ERP), and works closely with trusted psychotherapists who provide this specialized treatment.

Dr. Unverferth provides diagnostic evaluation, medication management, and recommendations for evidence-based psychotherapy, including exposure and response prevention. She has experience prescribing antidepressants for perinatal OCD, including at the higher doses often required to adequately treat this condition.

She has also provided national education on differentiating postpartum OCD from postpartum psychosis, including a 2026 expert interview on the Psychiatry & Psychotherapy Podcast with Dr. David Puder, discussing intrusive thoughts of infant harm, clinical assessment, and evidence-based treatment.

Perimenopausal Depression and Anxiety

Hormone levels can fluctuate substantially during perimenopause before declining overall as women approach menopause. For women who are sensitive to hormonal changes, this transition can lead to new or worsening insomnia, anxiety, and depression. Many women also report a lack of motivation, prominent irritability, and changes in their ability to manage stress.

Dr. Unverferth has extensive clinical experience treating perimenopausal mood and anxiety disorders. She serves as a consulting psychiatrist for UCLA's Comprehensive Menopause Care program, where she helped develop the psychiatric component of the program, including evidence-based approaches to managing depression, anxiety, insomnia, and other symptoms associated with the menopausal transition.

She also developed an extensive continuing medical education course on Mood and Anxiety Disorders During Perimenopause for the Psychopharmacology Institute, providing education to psychiatrists and other prescribing clinicians on hormonal mechanisms, diagnosis, and treatment. Her expertise in perimenopausal mental health has been featured in The Guardian, UCLA Health, and Shondaland.

Dr. Unverferth also treats women who are beginning to experience mood changes associated with the menopausal transition, even before they develop more recognizable physical symptoms of perimenopause. These women may notice increased irritability, anxiety, mood swings, or changes in sleep while continuing to have relatively regular menstrual cycles.

Her approach includes individualized assessment and treatment of perimenopausal depression and anxiety. Depending on the clinical presentation, treatment may include antidepressant medication, psychotherapy, and consideration of menopausal hormone therapy. Dr. Unverferth works closely with hormone specialists in the Los Angeles area to coordinate psychiatric treatment alongside menopausal hormone therapy when appropriate.

Infertility, Pregnancy Loss, and Reproductive Transitions

Infertility, pregnancy loss, and reproductive treatment can be associated with significant emotional distress, depression, and anxiety.

Dr. Unverferth provides psychiatric care for individuals navigating fertility treatment, pregnancy loss, and related reproductive experiences, including guidance about psychiatric medication use during fertility treatment and pregnancy planning.

Her approach recognizes the complex interaction between psychiatric symptoms, reproductive health, and individual circumstances. Treatment may include medication management, psychotherapy recommendations, and coordination with reproductive endocrinologists, OB/GYNs, and other members of the patient's care team.

General Adult Psychiatry

In addition to her reproductive psychiatry specialization, Dr. Unverferth treats adults with depression, anxiety disorders, and other mood-related concerns.

Her approach combines evidence-based psychiatric treatment with attention to each patient's medical history, life circumstances, and treatment goals.

Dr. Unverferth completed her psychiatry residency at UCLA, where she served as Chief Resident in Reproductive Psychiatry, followed by a fellowship in Mood Disorders at the UCLA Semel Institute for Neuroscience and Human Behavior. She is board-certified by the American Board of Psychiatry and Neurology and has maintained a private psychiatric practice in Santa Monica since 2019.